18F-FDG PET/CT显像监测卵巢癌术后复发转移的价值

目的:探讨PET/CT在监测卵巢癌术后复发、转移中的应用价值.方法:回顾性分析20例卵巢癌术后患者全身18F-FDG PET/CT显像结果,临床随访时间6～18个月.确诊依据为手术病理检查、穿刺活检、多种影像学检查和临床随诊.结果:20例患者中,13例(65%)患者最终确定有复发或转移,PET/CT诊断复发转移病例的灵敏度为100.0%,特异性为85.7%、准确性为95.0%.13例患者病理或随访确诊32处病灶, PET/CT共发现29处阳性病灶.PET/CT诊断复发或转移灶的灵敏度、特异性、准确率、阳性预测值及阴性预测值分别为84.3%(27/32)、81.8%(9/11)、83.7%(36/43)、93.1%(27/29)和64.2%(9/14).20例患者中,11例肿瘤标志CA125升高, 10例PET/CT检查显示复发或转移病灶,并经最终结果证实,1例血清CA125水平升高但PET/CT未检出转移灶,至随访结束未发现复发或转移.另有3例血清CA125水平正常,但PET/CT检查发现转移灶.结论:18F-FDG PET/CT检查诊断卵巢癌术后复发转移灵敏度、特异性和准确率较高,在卵巢癌术后监测中有重要作用.     

PET/CT鉴别肺癌中胸腔积液性质的临床价值

背景与目的 胸腔积液是肺癌患者常见的临床表现,鉴别胸水的性质有重要意义.正电子发射断层扫描/计算机体层摄影(positron emission tomography/computed tomography,PET/CT)是鉴别肺部良恶性肿瘤和纵隔淋巴结分期的重要诊断方法之一.本研究旨在探讨PET/CT鉴别肺癌中胸腔积液性质的临床价值.方法 回顾性分析合并胸腔积液的病理确诊的肺癌病例,以病理或临床随访为最后诊断标准,计算PET/CT诊断肺癌恶性胸腔积液的敏感性、特异性、阴性预测值、阳性预测值和准确率.结果 33例肺癌患者符合条件纳入分析PET/CT诊断肺癌恶性胸腔积液的敏感性、特异性、阳性预测值、阴性预测值和准确率分别为81.5％、83.3％、95.7％、50.0％和81.8％.结论 PET/CT对鉴别肺癌中胸腔积液的性质具有重要作用,假阳性率低,对PET/CT阴性的胸腔积液,需有创检查确认.     

子宫颈癌治疗后18F-FDG PET/CT显像的临床价值

目的 探讨18F-脱氧葡萄糖(FDG) PET/CT显像在子宫颈癌治疗后监测有无肿瘤复发及转移灶中的临床应用价值.方法 子宫颈癌治疗后患者48例,行全身18F-FDG PET/CT检查,肿瘤复发和(或)转移病灶根据病理结果、多种影像学诊断及临床随访而确诊.随访时间＞1年.采用SPSS 11.5软件进行统计学处理.结果 48例患者共行54次PET/CT显像,真阳性26例次,真阴性24例次,假阴性1例次,假阳性3例次.18F-FDG PET/CT显像诊断子宫颈癌治疗后肿瘤复发和(或)转移病灶的敏感度、特异性、准确性、阳性预测值及阴性预测值分别为96.3％ (26/27)、88.9％(24/27)、92.6％ (50/54)、89.7％(26/29)、96.0％(24/25).检查后部分患者的诊断和治疗方案发生了改变,有24例(50.0％)患者改变了诊断,其中21例(43.8％)改变了治疗方案.结论 PET/CT显像可以较准确地早期探查子宫颈癌治疗后的复发病灶和转移灶,包括盆腔外的远处转移,明确再分期,有助于临床医生确定正确的治疗方案.尽管有其一定的局限性,PET/CT显像仍可作为子宫颈癌治疗后监测的常规检查手段.     

FDG PET/CT对骨及软组织肿瘤诊断和疗效评价的应用

目的 探讨FDG PET/CT显像诊断骨或软组织肿瘤和术后疗效评价的价值.方法 回顾性分析48例已证实的骨及软组织肿瘤患者的FDG PET/CT显像结果,以鉴别诊断肿瘤的良恶性,是否复发、有无其他转移及周围侵犯,并与同机CT对比分析.结果 FDG PET/CT显像诊断骨及软组织肿瘤灵敏度为100%(7/7),特异性为80%(4/5);监测术后复发(残留)的灵敏度和特异性均为100%;通过PET/CT显像多发现转移灶35处,对于肺部12个转移灶,有赖于同机CT.结论 FDG PET/CT显像对骨及软组织肿瘤的诊断优于常规影像检查,可早期准确判断肿瘤复发,同时发现更多转移灶(肺转移除外),对肿瘤治疗诊断有指导作用.     

纵隔镜检查术在PET/CT纵隔淋巴结阳性的非小细胞肺癌中的应用北大核心CSCD

目的探讨纵隔镜检查术在纵隔或肺门淋巴结PET/CT(positron emission tomography-computed tomography)代谢阳性的非小细胞肺癌中(non-small cell lung cancer,NSCLC)的应用价值。方法回顾性分析纵隔镜检查术前PET/CT纵隔或肺门淋巴结异常的NSCLC病例,以病理结果为标准,计算纵隔镜检查术诊断纵隔淋巴结转移的敏感度、特异性、阳性预测值、阴性预测值和准确率以及PET/CT的假阳性率。结果 2007年4月—2011年12月期间,73例患者符合条件。纵隔镜检查术诊断纵隔淋巴结转移的敏感度、特异性、阳性预测值、阴性预测值和准确率分别为91.3%、100%、100%、87.1%和94.5%。PET/CT诊断纵隔淋巴结转移的假阳性率高达30.8%。如果将非巨块型纵隔淋巴结代谢升高且双侧肺门淋巴结代谢升高定义为纵隔淋巴结阴性,其阳性预测值升高至81.1%。结论在PET/CT纵隔或者肺门淋巴结代谢升高的NSCLC,纵隔镜检查术诊断纵隔淋巴结转移的敏感度和特异性高。对PET/CT代谢阳性的纵隔淋巴结需要病理确认,特别是合并双侧肺门对侧性代谢增高的纵隔淋巴结。     

^18F-FDG PET/CT显像在腮腺恶性肿瘤患者术后随访中的价值初探

目的探讨^18F-FDGPET/CT显像在腮腺恶性肿瘤术后患者随访中的临床应用价值。方法对12例腮腺恶性肿瘤术后患者（排除腮腺淋巴瘤及转移性肿瘤）的^18F-FDGPET/CT显像资料进行回顾性分析,并将其与CT或MRI及随访结果进行比较。结果^18F-FDGPET/CT显像对区域淋巴结转移的诊断灵敏度、特异性、准确率、阳性预测值和阴性预测值分别为100.0%、89.5%、91.7%、71.4%和100.0%,高于CT/MRI传统影像学检查的60.0%、68.4%、66.7%、33.3%和86.7%,且两者的准确率存在统计学差异（P〈0.05）。此外,^18F-FDGPET/CT显像诊断局部复发2例（1例假阳性）,检出远处转移灶及其它病变各3例。结论^18F-FDGPET/CT显像在腮腺恶性肿瘤术后患者的随访中有一定的意义,尤其对区域淋巴结转移的诊断有较高的价值。     

18F-FDG PET/CT与血清CEA测定联合应用对结直肠癌术后复发与转移的临床诊断价值

[目的]探讨18F-FDGPET／CT在结直肠癌术后血清CEA升高患者探测复发及转移灶中的应用。[方法]64例结直肠癌术后血清CEA升高患者均进行了18F-FDGPET／CT显像,并与病理及临床随访结果进行比较。[结果]PET／CT诊断阳性56例,1例假阳性;阴性8例,2例假阴性。PET／CT诊断灵敏度为96．5％,特异性为85．7％,阳性预测值为98.2％,阴性预测值为75．0％,准确率为93．8％。[结论]应用18F-FDGPET／CT检查对于结直肠癌术后血清CEA升高患者复发及转移灶的探测具有较高的灵敏度及特异性,血清CEA升高可以作为18F-FDGPET／CT检查前初筛的良好指标。     

18F-FDG PET/CT在419例肺外科患者中的应用经验

背景与目的我国是肺癌的高发国家,PET/CT在我国的肺外科临床应用价值仍处在探索阶段。本研究总结病理证实的419例肺部肿瘤或肿瘤样病变的患者资料,探讨PET/CT在这一领域的应用价值。方法 2007年12月-2011年8月北京大学肿瘤医院胸外一科单个医疗组对594例肺部肿瘤或肿瘤样病变的患者在诊治过程的不同阶段进行了PET/CT检查,以获得病理的419例患者为研究对象,结合临床、病理及随访,分析PET/CT在良恶性定性,肺癌TNM分期,疗效评价及疗后随访中的应用价值。结果全组419例患者中病理证实为良性者63例,恶性者356例,其中原发性肺癌338例,肺转移瘤18例。PET/CT对恶性肿瘤定性诊断(SUVmax>2.5)的敏感性为85.0%,特异性为52.4%,准确性79.2%,阳性预测值89.2%,阴性预测值42.9%。338例患者中治疗前行PET/CT者275例,共发现远处转移46例(46/275,16.7%),较传统检查(38/275,13.8%)多发现8例。对临床怀疑术后复发者(89例)行PET/CT,发现复发43例(43/89,48.3%),较传统检查(37/89,41.6%)多发现6例。对手术的168例患者作了T及N分期相关性的研究,发现SUVmax与肿瘤直径正相关(P<0.05)。清扫淋巴结共计610组,PET/CT诊断肺癌淋巴结转移的敏感性为36.3%,特异性为93.9%,准确性为84.3%,阳性预测值为54.4%,阴性预测值为88.0%。全组有10例患者化疗前后均作了PET/CT,SUVmax随肿瘤降期而下降,下降平均百分比为37.5%(P<0.05)。结论 PET/CT是现阶段除组织学外另一种可选的判断肺部良恶性病变的方法。PET/CT在肺癌M分期中的作用优于传统检查;也可作为术后复查的常规手段之一。PET/CT对淋巴结转移的诊断特异性较好,但敏感性不高。PET/CT在肺癌化疗评效中有积极意义。     

FDG-PET/CT在鼻咽癌放疗后随访中的初步应用研究

背景与目的:既往主要依靠CT、MRI、SPE/CT、PET检查来判断鼻咽癌(nasopharyngeal carcinoma,NPC)放疗后局部复发、肿瘤残留或全身转移情况,本研究拟探讨脱氧葡萄糖-正电子发射计算机断层(FDG-PET/CT)在判断NPC放疗后局部复发及全身转移中的应用价值.方法:38例NPC均已临床确诊并经放疗后行PET/CT检查,显像时间为放疗后3～36个月,分别观察PET/CT、PET、CT图像,PET以标准摄取值SUV＞2.5定为18F-FDG代谢增高.注射18F-FDG 7.4 MBq/kg后30 min后行脑显像,l h后行全身显像,部分患者行2 h延迟显像.结合CT的形态学特征和PET图像表现将38例患者观察结果分4组:(1)局部无复发、全身无转移;(2)局部有复发全身无转移;(3)局部无复发、全身有转移;(4)局部有复发、全身有转移.所有病例的最后诊断依赖于随访,随访时间6～10个月.结果:PET/CT诊断的敏感性为100%、特异性为89.5%,高于单独PET的100%和80%,明显高于单独CT的77.8%和84.2%.结论:PET/CT对NPC放疗后有无局部复发或肿瘤残留及全身转移的综合判断优于单独CT,略优于单独PET,在判断病灶是否为转移灶时,PET/CT的CT影像能提供重要的参考信息,对指导临床的诊治具有更好的帮助.     

18F-FDG PET/CT显像在胰腺癌诊断中的价值

目的 探讨18F-FDG PET/CT显像诊断胰腺癌中的临床价值.方法 回顾性分析我院近5年18F-FDG PET/CT显像发现胰腺肿块并行手术治疗的病例87例,将PET/CT显像的诊断结果与术后病理对照,探究18F-FDG PET/CT显像诊断胰腺癌的准确率、敏感性及特异性.结果 所有18F-FDG PET/CT显像发现胰腺肿块的病例中,18F-FDGPET/CT显像诊断为胰腺癌76例,其中术后病理结果为胰腺癌72例,胰腺滤泡型树突状细胞肉瘤1例,胰腺局限性炎症2例,胰岛素瘤1例:18F-FDG PET/CT诊断为良性肿瘤11例,其中术后病理证实胰岛素瘤5例,实质性假乳头状瘤2例,囊腺瘤2例,胰腺粘液腺癌2例.18F-FDG PET/CT显像对胰腺癌诊断的准确率为93.10％,敏感性为97.30％,特异性为69.23％.结论 18F-FDGPET/CT显像对胰腺癌诊断有较高的准确率,优于CT检查,具有重要的临床价值.     

18F‐Fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma

BACKGROUND:

The clinical utility of modern hybrid imaging modalities for detecting recurrent bone or soft tissue sarcoma remains to be determined. In this report, the authors present a clinical study on the diagnostic accuracy and incremental value of integrated ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F‐FDG PET/CT) in patients with a history of sarcoma who have clinically suspected disease recurrence.

METHODS:

Forty‐three patients who had a history of bone or soft tissue sarcoma and had documented complete remission underwent ¹⁸F‐FDG PET/CT. Image analysis was performed independently for ¹⁸F‐FDG PET (n = 43) and for contrast‐enhanced spiral CT (CE‐CT) (n = 30) by 2 separate readers, whereas combined ¹⁸F‐FDG PET/CT (n = 43) images were analyzed in consensus by both readers. Imaging findings were rated on a 5‐point scale and finally were reported as malignant, benign, or equivocal. Imaging findings were validated either by histopathology (n = 24) or by clinical follow‐up (n = 19).

RESULTS:

¹⁸F‐FDG PET/CT had greater sensitivity and specificity compared with CE‐CT alone (94% and 92% vs 78% and 67%, respectively), resulting in significantly greater accuracy (93% vs 73%; P = .03). ¹⁸F‐FDG PET/CT was particularly superior regarding detection of local recurrence or soft tissue lesions (sensitivity and specificity: 83% and 100% vs 50% and 100%, respectively) or bone metastases (100% and 100% vs 85% and 88%, respectively).

CONCLUSIONS:

¹⁸F‐FDG PET/CT had greater diagnostic accuracy in the detection of recurrent bone or soft tissue sarcoma compared with CE‐CT alone. The detection of local recurrence was the most evident advantage of ¹⁸F‐FDG PET/CT over CE‐CT. Cancer 2013. © 2012 American Cancer Society.     

PET/CT显像在妇科恶性肿瘤术后复发及转移中的临床应用价值

目的:探讨正电子发射断层显像(PET/CT)在诊断妇科恶性肿瘤术后复发与转移中的临床应用价值。方法:回顾性分析2015年1月至2016年12月,在我中心行PET/CT检查的56例妇科恶性肿瘤术后患者的全身PET/CT的显像结果,确诊依据为术后病理结果、血糖类抗原125（CA125）持续升高水平和临床随诊结果,评价PET/CT对妇科恶性肿瘤术后复发、转移的诊断效能。结果:56例患者中,经病理结果、血CA125持续升高水平、临床随诊结果证实,肿瘤复发及转移者25例,没有复发、转移者26例,假阳性者3例,假阴性者2例,PET/CT显像在妇科恶性肿瘤术后复发及转移的灵敏度、特异性、准确率分别为92.6%（25/27）、89.7%（26/29）、91.1%（51/56）;转移灶分为阴道残端、全身淋巴结、远处器官转移,PET/CT显像对各转移灶的灵敏度及特异性分别为87.5%(7/8)和97.9%(47/48)、95.0%（19/20）和91.7%（33/36）、91.3%（21/23）和90.9%（30/33）;PET/CT显像发现全身多部位、多器官转移的6人,改变了临床分期及治疗方案。结论:PET/CT显像对妇科恶性肿瘤术后复发及转移的诊断,具有较高的灵敏度和特异性,对肿瘤术后复发及转移的临床分期及治疗方案的确定具有非常大的指导意义。     

A study on the clinical value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography combined with serum squamous cell carcinoma antigen in diagnosing recurrence/metastases in patients with early metaphase cervical cancer

Cervical cancer (CC) is the most common female genital tract malignancy, with repercussions on the psychophysiological health of female patients. Patients with CC are faced with a high risk of postoperative recurrence and metastases. The present study aimed to evaluate the clinical value of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) combined with serum squamous cell carcinoma antigen (SCC-Ag) in the diagnosis of postoperative recurrence/metastases in patients with early stage CC. This was a prospective follow-up study on 246 patients who received surgery for early stage CC. The results of clinical follow-up and pathological examination were taken as the gold standard. The diagnostic sensitivity, specificity, positive predictive value, negative predictive value and area under the receiver operating characteristic (ROC) curve were calculated for PET/CT, serum SCC-Ag determination and the combined PET/CT and serum SCC-Ag method. Results demonstrated that 90.11% patients completed the follow-up, and the median follow-up time was 22 months (range, 7–42 months). Tumor recurrence or metastasis was confirmed in a total of 137 patients (55.7%), including 18 deaths. The diagnostic sensitivity of PET/CT scan combined with serum SCC-Ag determination for postoperative metastases/recurrence in patients with early stage CC was 93.43% (95% CI, 0.875–0.967). The specificity was 92.67% (95% CI, 0.856–0.965), the positive predictive value was 94.12% (95% CI, 0.884–0.972), the negative predictive value was 91.81% (95% CI, 0.846–0.959) and the area under the ROC curve was 0.930±0.019 (95% CI, 0.893–0.968; P<0.001). The results also revealed that the serum SCC-Ag level was positively correlated with SUVmax (r=0.458; P<0.001). The results from the present study demonstrated that for patients with early metaphase CC, PET/CT scan combined with serum SCC-Ag determination during the follow-up was capable of earlier, more comprehensive and more accurate detection of recurrence/metastatic lesions, which is of high clinical application value.     

PET/CT在卵巢癌术后监测复发/转移上的优势:与血清CA125及增强CT比较

目的:探讨18F-脱氧葡萄糖(18F-FDG)PET/CT在早期发现卵巢癌术后复发/转移方面的价值,并与血清CA125检测及增强CT进行比较。方法:回顾性分析过去5年内在我院行卵巢癌二次手术,并在术前均行血清CA125、增强CT、PET/CT检查的患者36例（99个病灶）。分别计算出以患者个体为研究单位时血清CA125及PET/CT检查的阳性预测值、阴性预测值、灵敏度、特异度、准确度等参数,并比较二者在监测卵巢癌术后个体复发/转移方面的效能。采用卡方检验或Fisher确切概率法来比较增强CT、PET/CT两种方法诊断卵巢癌术后转移/复发病灶的差异性,并分别计算出以病灶为研究单位时的阳性预测值、阴性预测值、灵敏度、特异度、准确度等参数,比较二者在诊断卵巢癌术后复发/转移病灶方面的效能。结果:PET/CT诊断出34/36例复发/转移的患者,而血清CA125以0~35 U/ml为基准时仅诊断出11/36例复发/转移的患者。前者诊断卵巢癌术后复发/转移患者的阳性预测值、灵敏度、准确度明显高于后者（97%、100%、97% vs 91%、32%、33%）。PET/CT与增强CT在诊断卵巢癌术后复发/转移病灶效能方面差异具有统计学意义（P=0.037）。PET/CT能够诊断出78/99个卵巢癌术后复发/转移的真阳性病灶,而增强CT仅能够诊断出70/99个。PET/CT以病灶为研究单位的阳性预测值、阴性预测值、灵敏度、特异度、准确度均比增强CT高（94% vs 89%、62.5% vs 30%、93% vs 83%、67% vs 40%、89% vs 77%）。结论:对于符合二次手术条件的患者,PET/CT诊断卵巢癌术后复发/转移方面的价值要优于血清CA125及增强CT。     

The diagnostic and prognostic utility of positron emission tomography/computed tomography‐based follow‐up after radiotherapy for head and neck cancer

BACKGROUND:

The detection of subclinical head and neck cancer recurrence or a second primary tumor may improve survival. In the current study, the authors investigated the clinical value of a follow‐up program incorporating serial ¹⁸F?fluorodeoxyglucose?positron emission tomography integrated with computed tomography (PET/CT) in the detection of recurrent disease in patients with head and neck cancer.

METHODS:

A total of 240 PET/CT scans were reviewed in 80 patients with head and neck cancer who were treated with radiotherapy (RT) from July, 2005 through August, 2007. All patients were followed with clinical examination, PET/CT, and correlative imaging for a minimum of 11 months (median follow?up, 21 months).

RESULTS:

The sensitivity, specificity, and positive and negative predictive values of PET/CT‐based follow‐up for detecting locoregional recurrence were 92%, 82%, 42%, and 98%, respectively. Corresponding values for distant metastases or second primary tumors were 93%, 96%, 81%, and 98%, respectively. Eight patients (10%) developed disease recurrences or second primary tumors that were amenable to salvage surgery with negative surgical margins. The 2‐year progression‐free survival and 2‐year overall survival rates were significantly different between patients who had a negative and those with a positive PET/CT result within 6 months of the completion of RT (93% vs 30% [P<.001] and 100% vs 32% [P<.001], respectively).

CONCLUSIONS:

Although post‐therapy follow‐up using PET/CT is reportedly associated with a high false‐positive rate in the irradiated head and neck, PET/CT appears to be a highly sensitive technique for the detection of recurrent disease. Furthermore, negative PET/CT results within 6 months of the completion of RT offer significant prognostic value. Cancer 2009. © 2009 American Cancer Society.     

1818F-FDG PET显像在胃肠道恶性肿瘤术后监测的应用价值

目的:探讨18F-双脱氧葡萄糖(FDG)PET显像探察胃肠道恶性肿瘤患者术后肿瘤复发和远处转移的应用价值。方法:40例胃肠道恶性肿瘤术后患者,其中食管癌8例,胃癌8例,结肠癌15例,直肠癌9例;进行18F-FDG显像。结果:18F-FDGPET显像诊断胃肠道恶性肿瘤术后复发和或转移的灵敏度93.8%、特异性87.5%、准确性92.5%;在18F-FDGPET显像真阳性30例中,4例为局部复发,9例为局部复发伴转移;17例为远处转移。在有复发的13例中,9例18F-FDGPET显像结果与X-CT结果一致,4例X-CT检查未见异常。在有转移的26例患者中,18F-FDGPET显像共捡出转移灶109处。结论:18F-FDGPET显像是检测胃肠道恶性肿瘤术后复发和转移的灵敏而有效的方法,值得推广应用。     

18F-FDG PET/CT在乳腺癌术后患者复发转移的诊断、治疗中的临床应用价值

目的探讨18F-FDG PET/CT对乳腺癌术后患者复发及转移诊断、治疗中的临床价值。方法收集并回顾性分析行18F-FDG PET/CT检查的94例女性乳腺癌术后患者,病理类型均为浸润性导管癌,年龄为28~79岁。患者均进行18F-FDG PET/CT全身显像,检测结果均应用半定量分析法和目测法判断。分析18F-FDG PET/CT对真阳性患者临床治疗策略的影响。结果18F-FDG PET/CT诊断乳腺癌术后复发转移的灵敏度、特异性、准确度、阳性预测值和阴性预测值分别为96.92%、89.65%、94.68%、91.30%、92.85%。依据18F-FDG PET/CT结果,58.51%真阳性患者最终更改了治疗方案。结论18F-FDG PET/CT能够有效评估乳腺癌术后复发及转移病例并且指导乳腺癌患者的临床治疗。     

18 F-PSMA-1007 PET/CT对前列腺癌根治术后生化复发患者早期诊断评估和临床治疗决策影响的价值研究

背景与目的： ¹⁸ F-前列腺特异性膜抗原（prostate-specific membrane antigen,PSMA）-1007正电子发射计算机体层显像（positron emission tomography and computed tomography,PET/CT）是目前前列腺癌（prostate cancer,PCa）评估的先进分子影像学手段。探讨 ¹⁸ F-PSMA-1007 PET/CT对PCa根治术（radical prostatectomy,RP）后生化复发（biochemical recurrence,BCR）患者临床复发和转移的早期检出率以及对临床治疗决策的影响。方法：总结分析2018年12月—2020年12月四川省肿瘤医院收治的行RP后BCR并行 ¹⁸ F-PSMA-1007 PET/CT检查的51例PCa患者的资料,采用感兴趣区方法半定量计算分析肿瘤放射性摄取,以最大标准化摄取值（maximum standardized uptake value,SUV _max ）表示。评估其对BCR患者临床复发和转移灶［局部复发（前列腺床）、淋巴结转移（盆腔、腹膜后和膈上等）、骨转移和内脏转移（如肺）］的检出率,进一步分别比较不同前列腺特异性抗原（prostate-specific antigen,PSA）水平组间和原Gleason评分组间检出率的差异。结果：51例患者的中位年龄为66岁（52~80岁）,初诊时血清中位PSA为35 ng/mL（6~224 ng/mL）。所有患者均为前列腺腺泡腺癌,其中1例伴导管内癌,1例伴导管腺癌,1例伴黏液腺癌,1例伴印戒样成分,1例伴神经内分泌分化。Gleason评分≤7分22例（43.14%）,Gleason评分≥8分29例（56.86%）。BCR发生的中位时间为15个月（3~62个月）,BCR时中位PSA为0.58 ng/mL（0.2~110.0 ng/mL）,其中0.2 ng/mL≤PSA ＜ 0.5 ng/mL 21例（41.18%）,0.5 ng/mL≤PSA ＜ 1.0 ng/mL12例（23.53%）,1.0 ng/mL≤PSA ＜ 2.0 ng/mL 4例（7.84%）,PSA≥2.0 ng/mL 14例（27.45%）。检查发现无临床局部复发或转移7例（13.73%）,临床局部复发或转移44例（86.27%）,其中9例（20.45%）前列腺术区复发,28例（63.64%）不同部位淋巴结转移,31例（70.45%）骨转移,2例（4.55%）内脏转移,此外还有2例皮下结节转移及1例阴茎根部转移。所有复发或转移灶的中位SUV _max 为17.9（1.4~110.9）,局部复发灶的中位SUV _max 为14.0（3.2~110.9）,淋巴结转移灶的中位SUV _max为10.2（2.0~90.1）,骨转移灶的中位SUV max 为5.4（1.4~109.6）。0.2 ng/mL≤PSA ＜ 0.5 ng/mL组（21例）、0.5 ng/mL≤PSA ＜ 1.0 ng/mL组（12例）、1.0 ng/mL≤PSA ＜ 2.0 ng/mL组（4例）和PSA≥2.0 ng/mL组（14例）的复发或转移检出率分别为71.43%（15/21）、100.00%（12/12）、75.00%（3/4）和100.00%（14/14）,不同PSA水平组间检出率差异无统计学意义（P＞0.05）。原Gleason评分≤7分组（22例）和Gleason评分≥8分组（29例）的复发或转移检出率分别为68.18%（15/22）和100.00%（29/29）,不同Gleason评分组间检出率差异有统计学意义（P ＜ 0.05）。临床治疗方面,采用观察等待4例（7.84%）,单纯内分泌治疗18例（35.29%）,单纯挽救性放疗（salvage radiotherapy,SRT）2例（3.92%）,内分泌治疗联合SRT 24例（47.06%）,内分泌治疗联合多西他赛全身化疗1例（1.96%）,挽救性盆腔淋巴结清扫术2例（3.92%）,最终共有30例（58.82%）患者改变原临床治疗决策。结论： ¹⁸ F-PSMA-1007 PET/CT对RP后BCR患者临床复发或转移具有很好的早期诊断价值和效能,有利于此类患者的精准评估和制定最优的治疗方案,并显著影响临床治疗决策。